Biotech · Public company · New York, NY, US
Tg Therapeutics, Inc.
Ticker TGTX · SEC CIK 0001001316
Track this companyFree. Adds Tg Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2514 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline22
- ChlorambucilPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FingolimodPhase 3 · Relapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- TGR-1202Phase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 3 · Relapsing Multiple Sclerosis (RMS)ClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 3 · Relapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- UmbralisibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib Oral CapsulePhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 2 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 2 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 2 · Myasthenia GravisClinicalTrials.gov · fetched Nov 12, 2026
- UmbralisibPhase 2 · Marginal Zone LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- UmbralisibPhase 2 · Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Azercabtagene zapreleucel (azer-cel)Phase 1 · B-cell Mediated Autoimmune DisordersClinicalTrials.gov · fetched Nov 12, 2026
- TG-1801Phase 1 · CLLClinicalTrials.gov · fetched Nov 12, 2026
- UblituximabPhase 1 · CLLClinicalTrials.gov · fetched Nov 12, 2026
- No interventionMultiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionB-cell Mediated Autoimmune DisordersClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionRelapsing Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Long-term Follow-up (LTFU) of Participants Who Received Azer-CelRECRUITING · started May 1, 2027ClinicalTrials.gov NCT07577583 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)PHASE2 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07673744 · fetched Nov 12, 2026
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaPHASE2 · RECRUITING · started Jul 27, 2026ClinicalTrials.gov NCT07680946 · fetched Nov 12, 2026
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisPHASE2_PHASE3 · RECRUITING · started Jul 1, 2026ClinicalTrials.gov NCT07220252 · fetched Nov 12, 2026
- Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple SclerosisNA · RECRUITING · started May 1, 2026ClinicalTrials.gov NCT06864936 · fetched Nov 12, 2026
- Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisPHASE4 · RECRUITING · started Feb 10, 2026ClinicalTrials.gov NCT07389590 · fetched Nov 12, 2026
- Ublituximab (Briumvi) for Early Forms of Relapsing Multiple SclerosisPHASE4 · RECRUITING · started Nov 28, 2025ClinicalTrials.gov NCT07225361 · fetched Nov 12, 2026
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersPHASE1 · RECRUITING · started May 6, 2025ClinicalTrials.gov NCT06680037 · fetched Nov 12, 2026
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)RECRUITING · started Jul 22, 2024ClinicalTrials.gov NCT06433752 · fetched Nov 12, 2026
- A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)RECRUITING · started Jun 1, 2024ClinicalTrials.gov NCT06433765 · fetched Nov 12, 2026
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkACTIVE_NOT_RECRUITING · started Mar 26, 2024ClinicalTrials.gov NCT06143514 · fetched Nov 12, 2026
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPHASE3 · RECRUITING · started Jun 13, 2023ClinicalTrials.gov NCT05877963 · fetched Nov 12, 2026
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaPHASE1 · TERMINATED · started Apr 28, 2021ClinicalTrials.gov NCT04806035 · fetched Nov 12, 2026
- Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel TherapyPHASE2 · TERMINATED · started Feb 10, 2021ClinicalTrials.gov NCT04149821 · fetched Nov 12, 2026
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 15, 2020ClinicalTrials.gov NCT04624633 · fetched Nov 12, 2026
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisPHASE3 · ACTIVE_NOT_RECRUITING · started Nov 18, 2019ClinicalTrials.gov NCT04130997 · fetched Nov 12, 2026
- TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)PHASE2 · TERMINATED · started Nov 12, 2019ClinicalTrials.gov NCT04163718 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxPHASE2 · TERMINATED · started Aug 5, 2019ClinicalTrials.gov NCT04016805 · fetched Nov 12, 2026
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaPHASE2 · TERMINATED · started Jul 10, 2019ClinicalTrials.gov NCT03828448 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)PHASE2_PHASE3 · TERMINATED · started May 16, 2019ClinicalTrials.gov NCT03801525 · fetched Nov 12, 2026
- Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaPHASE2 · COMPLETED · started Nov 30, 2017ClinicalTrials.gov NCT03364231 · fetched Nov 12, 2026
- Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyPHASE2 · TERMINATED · started Apr 21, 2016ClinicalTrials.gov NCT02742090 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304PHASE2 · TERMINATED · started Jan 7, 2016ClinicalTrials.gov NCT02656303 · fetched Nov 12, 2026
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaPHASE3 · TERMINATED · started Nov 19, 2015ClinicalTrials.gov NCT02612311 · fetched Nov 12, 2026
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLPHASE1 · COMPLETED · started Nov 1, 2014ClinicalTrials.gov NCT02268851 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 27, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 20, 2026 · fetched Nov 12, 2026
- 10-K · FORM 10-KSEC EDGAR · filed Feb 27, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026